Harrow, Inc. (NASDAQ:HROW) Shares Sold by D.A. Davidson & CO.

D.A. Davidson & CO. reduced its stake in Harrow, Inc. (NASDAQ:HROW) by 1.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 60,913 shares of the company’s stock after selling 1,028 shares during the quarter. D.A. Davidson & CO. owned 0.17% of Harrow worth $2,044,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. JPMorgan Chase & Co. lifted its holdings in shares of Harrow by 443.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 238,367 shares of the company’s stock worth $10,717,000 after acquiring an additional 194,480 shares during the last quarter. Oppenheimer & Co. Inc. acquired a new position in shares of Harrow in the 3rd quarter worth approximately $1,267,000. Penserra Capital Management LLC acquired a new position in shares of Harrow in the 3rd quarter worth approximately $1,986,000. Semanteon Capital Management LP acquired a new position in shares of Harrow in the 3rd quarter worth approximately $686,000. Finally, Barclays PLC increased its stake in Harrow by 301.9% during the 3rd quarter. Barclays PLC now owns 52,593 shares of the company’s stock worth $2,365,000 after buying an additional 39,506 shares during the period. 72.76% of the stock is currently owned by institutional investors and hedge funds.

Harrow Trading Down 3.9 %

Shares of NASDAQ:HROW opened at $28.95 on Friday. Harrow, Inc. has a 52 week low of $9.30 and a 52 week high of $59.23. The company’s 50 day moving average is $33.22 and its two-hundred day moving average is $40.06. The company has a current ratio of 1.55, a quick ratio of 1.44 and a debt-to-equity ratio of 3.23. The company has a market cap of $1.03 billion, a PE ratio of -30.80 and a beta of 0.69.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. HC Wainwright assumed coverage on shares of Harrow in a research note on Thursday, February 6th. They set a “buy” rating and a $57.00 target price on the stock. B. Riley cut their target price on shares of Harrow from $73.00 to $69.00 and set a “buy” rating on the stock in a research note on Wednesday, December 4th.

Harrow Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.